Editorial gram (ECG) and elevations in the creatine kinase MB subfraction (CK-MB) to appropriately determine myocardial injury. 8, 9 The previous gold standard marker of myocardial infarction was CK-MB isoenzyme used both in cardiac surgery and in acute coronary syndromes to aid in the diagnosis of myocardial infarction. However, the sensitivity and specificity of this marker has been demonstrated to be reduced compared with the new assessments of troponin levels (troponin T, cTnT; troponin I, cTnI). [10] [11] [12] Can these gold standards be improved through advanced laboratory technology? Greenson et al continue this ongoing question in their accompanying article defining "the usefulness of cTnI in patients undergoing open heart surgery." Greenson et al demonstrate improved specificity and sensitivity of troponin I compared with CK-MB in the prediction of both Q-wave MI and new regional wall motion abnormalities assessed by echocardiography. Both moderate (40-60 ng/mL) and severe (60 ng/mL) elevations of cTnI were significantly associated with ischemic ECG changes and new left ventricular wall motion abnormalities by echocardiography, as well as prolonged intubation, intensive care unit stay, intra-aortic balloon pump use, and arrhythmias. Greenson et al went on to define the positive as well as negative predictive power of their observed changes. The study demonstrates the importance of sensitivity and specificity of troponin I in predicting overall outcome, which is consistent with studies by Gensini 13 but is in stark contrast to the recently reported data from Horvath 9 demonstrating poor correlations between cTnI and ECG and transesophageal echocardiography changes. A substantial difference in the method is the timing of measurements in the two studies. Greenson et al demonstrated peak levels of cTnI 36 hours postoperatively. Horvath et al 9 had no measurements at this time frame or at 24 and 48 hours, measuring only at 1, 6, and 72 hours postoperatively. Missing the primary elevation on the basis of sample timing would likely reduce the value of the assessment in predicting myocardial damage assessed by other end points. However, the demonstration that cTnI was extremely high in shed blood and that the return of this blood to the patient could artificially elevate levels is an important issue for further study. 9 The results of both studies may be predictable by the time frame in which each measured cardiac markers. By excluding early assessment and concentrating on the late follow-up Greenson et al enhanced the probability that cTnI and not CK-MB would have the larger predictive power because peak levels of CK-MB could have been missed.
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See related article on page 447.
Coronary artery bypass grafting and valvular surgery have become extremely safe procedures with patients now undergoing operations well into the ninth decade. 1 Despite the substantial advances in anesthetic management, surgical techniques, and myocardial preservation that has led to this continued improvement in morbidity and mortality, myocardial injury continues to occur in association with cardiac surgery. Although the incidence of this complication related to risk has declined, 2 the risk (increasing age, comorbidities, and lower ejection) has increased to maintain a perioperative myocardial infarction rate of 7% to 15%. 3, 4 Studies demonstrate that perioperative ischemic events are associated with substantial increases in complications and reductions in long-term survival. 5 Force et al 5 followed up 59 patients with myocardial infarction (MI) after coronary artery bypass grafting and 115 patients without perioperative MI for 30 months, assessing the development of cardiac events (death, nonfatal MI, and admission to hospital for unstable angina or congestive heart failure). Patients with perioperative MI were significantly more likely than patients without to have a cardiac event (31% vs 12%, P < .01) and multiple events (19% vs 1%, P < .001). Similar to other perioperative risk factors, the importance of MI to long-term outcome varied with respect to other environmental or procedural factors. The importance of appropriately measuring myocardial injury is underscored by recent trials demonstrating improved long-term survival with treatment or prevention of perioperative myocardial ischemia or infarction. 6, 7 Despite the incidence and importance of perioperative myocardial injury, there is substantial variance in measurement of cardiac isoenzymes after cardiac surgery in clinical practice, and even greater variability in how they are used. The large variation in reported incidence of myocardial injury is in part related to the measurement techniques or criteria used to define myocardial injury. Questions have arisen as to the reliability of gold standards, new Q-waves on electrocardio-If the substantial improvement in sensitivity and specificity and excellent correlation with perioperative complications demonstrated by Greenson et al can be confirmed in larger trials and the conflicting results from Horvath 9 resolved, cTnI would be a substantial advancement in the science of assessing myocardial injury associated with cardiac surgery. A number of important issues related to standardization of this measurement have been addressed in editorials elsewhere and must be considered as adoption of this technique as the routine approaches. 12, 14 The unanswered question is the value of the data in caring for our patients. Because there is a significant correlation between ECG and echocardiographyassessed myocardial injury with cTnI, it has become increasingly evident that cTnI may be the marker of choice to assess myocardial injury in ongoing clinical trials of myocardial protection. Demonstrated reduction of cTnI with clinical or pharmacologic interventionbased studies would be expected to improve hospital outcomes with additional trials necessary to determine how these factors relate to longer-term myocardial outcome and mortality. However, the value in clinical practice remains to be determined on the basis of our ability to predict individuals at high risk who require additional intensive monitoring, or therapy. Further, we must determine our ability to alter the progression of events through pharmacologic or other interventions to prevent the secondary outcomes associated with the perioperative myocardial injury demonstrated by elevated cTnI. Although the later peak associated with cTnI is not a limitation for assessment of myocardial injury in clinical trials, the importance of this delay in making available information for intervention will need to be determined. It may be that the gold standard for determination of myocardial injury varies by the period of measurement or that multiple markers with varying degrees of sensitivity and specificity by timing of release may provide a better measure. If cTnI can be an indicator of the need for further intervention to reduce long-term morbidity and mortality, it could be of substantial importance in helping us make a safe procedure even safer.
